跳至主要内容
临床试验/NCT01083199
NCT01083199已完成4 期

Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy

American Medical Systems2 个研究点 分布在 2 个国家目标入组 10 人开始时间: 2007年10月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
10
试验地点
2
主要终点
Successful Device Placement

研究概览

简要总结

  1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure.
  2. To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.

详细描述

Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed.

CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing.

The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •All males ≥ 40 years old who are indicated for a radical prostatectomy will be eligible to participate in the study

排除标准

  • •If contraindicated for surgery
  • •Inability to understand the study or a history of non-compliance with medical advice
  • •Unwilling or unable to sign an Informed Consent Form (ICF)
  • •A history of:
  • •Recurrent urinary tract infections (UTI)
  • •Recurrent stricture disease
  • •Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease)
  • •Uncontrolled insulin-dependent diabetes
  • •Chemotherapy within the past 6 months
  • •Non-topical steroid use within the past 6 months
  • •Allergy to nitinol, nickel, titanium or silicone

研究组 & 干预措施

CONTINUUMTM

Experimental

干预措施: CONTINUUM™ (Device)

结局指标

主要结局

Successful Device Placement

时间窗: During Radical Prostatectomy

Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.

Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement

时间窗: 7-21 days post-Device placement

Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window. The following defines the timeframe of each removal attempt: * 7-day window (7-10 days post-implant) * 14-day window (13-15 days post-implant) * 21-day window (19-21 days post-implant)

次要结局

  • Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits(7 and 14 days post-Device placement)
  • Incontinence Rate and I-QOL Score(Baseline, 6-week, 6 and 12-month evaluations)
  • Intraoperative/Postoperative Parameters(At Device placement)
  • Bladder Neck Contracture (BNC) Rate(Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验